Eagle Pharmaceuticals (EGRX) Income Statement
Eagle Pharmaceuticals Income Statement
Last quarter (Q2 2023), Eagle Pharmaceuticals's total revenue was $64.65M, a decrease of 12.80% from the same quarter last year. In Q2, Eagle Pharmaceuticals's net income was $5.16M. See Eagle Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| $ 316.61M | $ 171.55M | $ 187.80M | $ 195.89M | $ 213.31M | |
| $ 221.67M | $ 129.37M | $ 142.34M | $ 135.00M | $ 151.40M | |
| $ 140.71M | $ 126.60M | $ 109.38M | $ 113.18M | $ 104.93M | |
| Depreciation and Amortization | $ 12.02M | $ 3.76M | $ 4.77M | $ 4.65M | $ 3.67M |
| $ 77.50M | $ 847.00K | $ 30.02M | $ 29.34M | $ 40.44M | |
| $ 80.96M | $ 2.77M | $ 32.95M | $ 21.82M | $ 36.62M | |
| $ -19.53M | $ -7.32M | $ -10.28M | $ 183.00K | $ -2.58M | |
| $ 61.43M | $ -4.55M | $ 22.68M | $ 22.00M | $ 34.04M | |
| $ 35.64M | $ -8.63M | $ 11.99M | $ 14.31M | $ 31.90M | |
| Per Share Metrics | |||||
| Basic EPS | $ 2.76 | $ -0.66 | $ 0.89 | $ 1.04 | $ 2.16 |
| Diluted EPS | $ 2.73 | $ -0.66 | $ 0.87 | $ 1.01 | $ 2.09 |
| Weighted Average Shares Outstanding | 12.93M | 13.05M | 13.48M | 13.75M | 14.77M |
| Weighted Average Shares Outstanding (Diluted) | 13.07M | 13.05M | 13.77M | 14.14M | 15.28M |
Currency in USD